Alibaba
BABA
Tesla
TSLA
Netflix
NFLX
Broadcom
AVGO
Micron Technology
MU
US Stock MarketDetailed Quotes
AXSM Axsome Therapeutics
- 119.500
- +0.720+0.61%
Close Mar 11 16:00 ET
- 121.600
- +2.100+1.76%
Post 17:12 ET
5.83BMarket Cap-19.95P/E (TTM)
122.000High117.665Low824.70KVolume120.000Open118.780Pre Close98.23MTurnover2.25%Turnover RatioLossP/E (Static)48.77MShares139.13052wk High102.22P/B4.38BFloat Cap64.11052wk Low--Dividend TTM36.67MShs Float139.130Historical High--Div YieldTTM3.65%Amplitude1.940Historical Low119.111Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Axsome Therapeutics Stock Forum
Axsome Wins 16+ Years of Market Exclusivity for Sunosi in Patent Settlement
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Can This New Migraine Drug Replace CGRP Inhibitors? Trial Shows 48x Success Rate
Axsome Shatters Expectations: Record 89% Growth for Depression Drug Auvelity, Pipeline Milestones Accelerate
Axsome Wins Major Victory: 15+ Years Market Protection for AUVELITY Secured in Patent Deal
has options
nfa be careful
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$ Phase 3
$Aquestive Therapeutics (AQST.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$Johnson & Johnson (JNJ.US)$ Phase 3
No comment yet